Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CTSO logo CTSO
Upturn stock ratingUpturn stock rating
CTSO logo

Cytosorbents Crp (CTSO)

Upturn stock ratingUpturn stock rating
$1.28
Last Close (24-hour delay)
Profit since last BUY17.43%
upturn advisory
Consider higher Upturn Star rating
BUY since 13 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CTSO (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $5

1 Year Target Price $5

Analysts Price Target For last 52 week
$5Target price
Low$0.71
Current$1.28
high$1.61

Analysis of Past Performance

Type Stock
Historic Profit -33.46%
Avg. Invested days 20
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 77.01M USD
Price to earnings Ratio -
1Y Target Price 5
Price to earnings Ratio -
1Y Target Price 5
Volume (30-day avg) 2
Beta 1.05
52 Weeks Range 0.71 - 1.61
Updated Date 06/29/2025
52 Weeks Range 0.71 - 1.61
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.29

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -45.59%
Operating Margin (TTM) -44.54%

Management Effectiveness

Return on Assets (TTM) -20.46%
Return on Equity (TTM) -96.26%

Valuation

Trailing PE -
Forward PE 7.73
Enterprise Value 92400210
Price to Sales(TTM) 2.18
Enterprise Value 92400210
Price to Sales(TTM) 2.18
Enterprise Value to Revenue 2.62
Enterprise Value to EBITDA -1.92
Shares Outstanding 62610400
Shares Floating 54315127
Shares Outstanding 62610400
Shares Floating 54315127
Percent Insiders 15.29
Percent Institutions 27.77

Analyst Ratings

Rating 2
Target Price 5
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Cytosorbents Crp

stock logo

Company Overview

overview logo History and Background

CytoSorbents Corporation, founded in 2002, focuses on critical care immunotherapy through blood purification. Its initial focus was on removing inflammatory mediators in sepsis, expanding to address other critical conditions.

business area logo Core Business Areas

  • Critical Care: Develops and commercializes blood purification therapies for sepsis, acute respiratory distress syndrome (ARDS), and other critical illnesses. CytoSorb is their flagship product.
  • Cardiac Surgery: Offers blood purification technologies to mitigate inflammation during and after cardiac surgery.
  • Antithrombotic Removal: Develops products to remove antithrombotic drugs from the body in emergency situations, such as during bleeding complications.

leadership logo Leadership and Structure

Philip P. Chan is the CEO. The company has a board of directors and is structured with departments for R&D, manufacturing, sales, and marketing.

Top Products and Market Share

overview logo Key Offerings

  • CytoSorb: CytoSorb is a blood purification cartridge designed to remove excessive cytokines and other inflammatory mediators from the bloodstream. It is used in sepsis, ARDS, and other critical illnesses. CytoSorb has achieved regulatory approvals in the European Union and other countries. The market share is variable and dependent on region and indication, making it difficult to provide a precise figure. Key competitors include companies offering CRRT (Continuous Renal Replacement Therapy) and other blood purification techniques. Competitors for this include Baxter (BAX) and Fresenius Medical Care (FMS).
  • Ecosorb: Ecosorb is a blood purification cartridge designed to remove ticagrelor, a common antithrombotic drug. It aims to reverse antiplatelet effects in emergency situations such as bleeding complications. Exact market share data not publicly available due to it being a relatively new segment. Potential competitors could include other reversal agents if developed and approved.

Market Dynamics

industry overview logo Industry Overview

The blood purification market is driven by increasing rates of sepsis, ARDS, and other critical illnesses. Advances in technology and growing awareness of blood purification therapies contribute to market growth.

Positioning

CytoSorbents is positioned as a leader in blood purification for critical care, particularly in cytokine removal and antithrombotic reversal. Its competitive advantages lie in its CytoSorb technology and growing portfolio of products.

Total Addressable Market (TAM)

The estimated total addressable market (TAM) is in the billions of dollars, encompassing critical care, cardiac surgery, and antithrombotic removal applications. Cytosorbents is positioning itself to capture a significant share of this market, particularly with its Cytosorb and Ecosorb products

Upturn SWOT Analysis

Strengths

  • Proprietary CytoSorb technology
  • Regulatory approvals in EU and other countries
  • Expanding product portfolio
  • Strong research and development efforts
  • Experienced management team

Weaknesses

  • Limited commercial presence in the US
  • Dependence on key products like CytoSorb
  • Relatively small size compared to major players in blood purification
  • Funding and cashflow management
  • Geographic concentration of sales

Opportunities

  • Expansion into the US market
  • Development of new blood purification therapies
  • Partnerships with major healthcare providers
  • Increased adoption of blood purification in critical care
  • New regulatory approval for new products

Threats

  • Competition from established players in blood purification
  • Regulatory hurdles
  • Pricing pressures
  • Technological advancements by competitors
  • Changes in healthcare reimbursement policies

Competitors and Market Share

competitor logo Key Competitors

  • BAX
  • FMS
  • NXTM

Competitive Landscape

Cytosorbents Crp faces competition from larger, more established players in the blood purification market. Its competitive advantages include its proprietary CytoSorb technology and focus on critical care immunotherapy. However, competitors have greater resources and wider product portfolios.

Major Acquisitions

Medica S.p.A. CARDIOSORB business

  • Year: 2023
  • Acquisition Price (USD millions): 3.3
  • Strategic Rationale: The acquisition of the CARDIOSORB business expands Cytosorbents' portfolio in cardiac surgery and provides access to new markets and technologies.

Growth Trajectory and Initiatives

Historical Growth: Cytosorbents Crp has experienced significant revenue growth in recent years, driven by increasing adoption of CytoSorb and expanding geographic reach.

Future Projections: Analysts project continued revenue growth, driven by expansion into the US market and development of new products. Growth is projected to be 15%-20% per year for the next 3-5 years.

Recent Initiatives: Recent initiatives include expanding the US sales force, initiating clinical trials for new indications, and strategic partnerships with healthcare providers.

Summary

Cytosorbents is a small-cap company with a leading product in blood purification, but it faces stiff competition from larger companies. While Cytosorb has achieved regulatory success in Europe and other countries, its US market presence remains limited. Revenue growth has been strong; however, profitability remains elusive and requires careful monitoring. Expansion into the US market and the development of new products are critical for future growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (SEC)
  • Analyst reports
  • Industry publications
  • CytoSorbents Investor Relations

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Cytosorbents Crp

Exchange NASDAQ
Headquaters Princeton, NJ, United States
IPO Launch date 2013-11-07
CEO & Director Dr. Phillip P. Chan M.D., Ph.D.
Sector Healthcare
Industry Medical Devices
Full time employees 149
Full time employees 149

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.